<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">PCH</journal-id>
<journal-id journal-id-type="hwp">sppch</journal-id>
<journal-title>World Journal for Pediatric and Congenital Heart Surgery</journal-title>
<issn pub-type="ppub">2150-1351</issn>
<issn pub-type="epub">2150-0136</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/2150135111420888</article-id>
<article-id pub-id-type="publisher-id">10.1177_2150135111420888</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Proceedings of the Seventh International Conference on Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary Perfusion</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Intensive Care of the Pediatric Ventricular Assist Device Patient</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Hehir</surname>
<given-names>David A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-2150135111420888">1</xref>
<xref ref-type="aff" rid="aff2-2150135111420888">2</xref>
<xref ref-type="corresp" rid="corresp1-2150135111420888"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Niebler</surname>
<given-names>Robert A.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-2150135111420888">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Brabant</surname>
<given-names>Christopher C.</given-names>
</name>
<degrees>CCP</degrees>
<xref ref-type="aff" rid="aff2-2150135111420888">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tweddell</surname>
<given-names>James S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-2150135111420888">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ghanayem</surname>
<given-names>Nancy S.</given-names>
</name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-2150135111420888">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-2150135111420888"><label>1</label>Division of Pediatric Critical Care, Children’s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, USA</aff>
<aff id="aff2-2150135111420888"><label>2</label>Division of Pediatric Cardiology, Children’s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, USA</aff>
<aff id="aff3-2150135111420888"><label>3</label>Division of Cardiothoracic Surgery, Children’s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee, WI, USA</aff>
<author-notes>
<corresp id="corresp1-2150135111420888">David A. Hehir, Pediatric Critical Care Medicine, Children’s Hospital of Wisconsin, 9000 West Wisconsin Ave., MS #681, Milwaukee, WI 53226, USA Email: <email>dhehir@mcw.edu</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>3</volume>
<issue>1</issue>
<fpage>58</fpage>
<lpage>66</lpage>
<history>
<date date-type="received">
<day>17</day>
<month>5</month>
<year>2011</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>7</month>
<year>2011</year>
</date>
</history>
<permissions>
<copyright-statement>© World Society for Pediatric and Congential Heart Surgery 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">World Society for Pediatric and Congential Heart Surgery</copyright-holder>
</permissions>
<abstract>
<p>Utilization of ventricular assist devices (VADs) in children is increasing, as is the complexity of patients supported. We review the intensive care management of pediatric patients with VAD in the perioperative and rehabilitation phases, highlighting the technical aspects and physiology of VADs which impact care. Indications for VAD placement and the preoperative assessment of risk are discussed. Specific aspects of postoperative and long-term care including device troubleshooting, hemostasis and anticoagulation, support of the right ventricle, incidence and prevention of neurologic injury, and other complications are reviewed.</p>
</abstract>
<kwd-group>
<kwd>Ventricular assist device</kwd>
<kwd>mechanical circulatory support</kwd>
<kwd>intensive care</kwd>
<kwd>pediatrics</kwd>
<kwd>congenital heart disease</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-2150135111420888">
<title>Introduction</title>
<p>The use of ventricular assist devices (VADs) as a bridge to transplant or recovery in pediatric heart failure has steadily increased over recent years due to improvements in device technology, broadened indications for VAD placement, and improvements in postimplantation care. While morbidity and mortality remain high in current series of pediatric VAD use (62%-87% survival), this compares favorably with reported survival using a strategy of extracorporeal membrane oxygenation (ECMO) as a bridge to transplant (39-57%).<sup>
<xref ref-type="bibr" rid="bibr1-2150135111420888">1</xref>
<xref ref-type="bibr" rid="bibr2-2150135111420888"/>
<xref ref-type="bibr" rid="bibr3-2150135111420888"/>–<xref ref-type="bibr" rid="bibr4-2150135111420888">4</xref>
</sup> Ventricular assist devices have distinct advantages over ECMO, including longer potential duration of support, greater rehabilitation potential, and the promise of progressive organ recovery over time. These advantages, coupled with the challenges of ever-lengthening transplant wait times with a static donor pool and a fast-growing population of older congenital patients with developing heart failure, have further stimulated the development of improved VAD technology. Therefore, their use in the cardiac intensive care unit (ICU) will continue to grow, and it is paramount that the practitioner of pediatric cardiac critical care be familiar with the management strategies and potential complications associated with caring for the perioperative patient with VAD.</p>
<p>Intensive care of the pediatric patient following implantation of a VAD demands an understanding of both disease-specific as well as device-specific risk factors for morbidity. Effective ICU care of these patients involves a collaborative, multidisciplinary approach. Below, we will (1) review devices most commonly used in pediatrics for long-term mechanical support and discuss their impact on physiology; (2) outline goals of ICU care, in both the perioperative and long-term rehabilitation phases; and (3) highlight challenging clinical scenarios.</p>
</sec>
<sec id="section2-2150135111420888">
<title>Description of Devices</title>
<p>Utilization of VADs in the pediatric population has steadily increased in recent years, as innovation in device design and the adaptation of existing devices to pediatric applications continue to undergo rapid evolution.<sup>
<xref ref-type="bibr" rid="bibr5-2150135111420888">5</xref>
</sup> This has been accompanied by The National Heart, Lung, and Blood Institute (NHLBI) initiative “Pediatric Circulatory Support Program” (PCSP)<sup>
<xref ref-type="bibr" rid="bibr6-2150135111420888">6</xref>
</sup>, which began funding five contracts to develop novel pediatric circulatory support devices in March 2004. Advances in the design of devices targeted to the adult population such as third-generation axial flow devices (miniaturization, improved hemostatic qualities, simplified interfaces and power supplies, etc) have made them attractive options for larger children and have been studied in small series.<sup>
<xref ref-type="bibr" rid="bibr7-2150135111420888">7</xref>,<xref ref-type="bibr" rid="bibr8-2150135111420888">8</xref>
</sup> However, as the PCSP devices are either still in the laboratory or in early clinical phases, the only widely used pediatric-specific device available in North America for long-term implantation in a wide weight range remains the Berlin Heart EXCOR VAD (Berlin Heart AG, Berlin, Germany). The Thoratec VAD (Thoratec Corporation, Pleasanton, California) is the most commonly employed adult device in larger children (body surface area [BSA] &gt; 1.3 m<sup>2</sup>), and the Thoratec VAD along with the Berlin Heart EXCOR will be the focus of this review (<xref ref-type="fig" rid="fig1-2150135111420888">Figure 1</xref>
).</p>
<fig id="fig1-2150135111420888" position="float">
<label>Figure 1.</label>
<caption>
<p>Thoractec Ventricular Assist device (A) and Berlin Heart Excor (B, shown in the range of sizes, including those for pediatric use).</p>
</caption>
<graphic alternate-form-of="fig1-2150135111420888" xlink:href="10.1177_2150135111420888-fig1.tif"/>
</fig>
<p>The Berlin Heart EXCOR VAD is a pulsatile electropneumatic paracoporeal device available in a range of sizes for use in children and adults. It was first used in 1992 in Europe and is currently available in the United States for pediatric use under an unlimited investigational device exemption trial (IDE) while it undergoes consideration for full US Foodand Drug Administration (FDA) approval. The device consists of the blood pump, cannula, and the Ikus driver unit. The blood pump is clear allowing for inspection of fill and empty of the blood chamber, as well as visualization of clot formation in the blood chamber or on the inflow and outflow valves. The chamber is subdivided into blood and air compartments by a membrane, and the blood contact surfaces are Carmeda coated (San Antonio, Texas). The inlet and outlet of the blood chamber is equipped with valves which are either tilting-disk type (50-80 mL) or tri-leaflet (all sizes). The cannulae are available in three configurations: atrial, apical, and arterial. Cannulation is achieved through the anterior abdominal wall, typically with the inflow cannula in the left ventricular (LV) apex position and outflow cannula in the ascending aorta. The Ikus 2000 driver unit provides the pneumatic systems to move the membrane and a laptop user interface, allowing intuitive control of the adjustable parameters (rate, percentage systole, and drive pressure). The EXCOR functions in a fixed rate mode only, which can be adjusted from 30 to 150 beats/min; during the use of biventricular assist device (BiVAD), both synchronous and asynchronous modes are available.</p>
<p>The Thoratec VAD is a pneumatically driven paracorporeal pulsatile device limited to larger children due to a 65-mL chamber size. Depending on device settings and patient characteristics, this allows delivery of cardiac output from 1.3 to 7.1 L/min. Like the Berlin Heart Excor, cannulae are tunneled through the anterior abdominal wall and diaphragm. The most common cannulation technique is LV to aorta, with left atrial cannulation also an option. The Thoratec VAD is powered by a pneumatic driver, with two modes of operation: fill-to-empty or volume mode and fixed rate or asynchronous mode. Due to blood chamber volume, this device is limited to larger children: an analysis<sup>
<xref ref-type="bibr" rid="bibr9-2150135111420888">9</xref>
</sup> of pediatric implants recorded in the company database found a mean age of 14.5 years (range 5-18 years), mean weight 57 kg (range 17-118 kg), and mean BSA 1.6 m<sup>2</sup> (range 0.7-2.3 m<sup>2</sup>).</p>
</sec>
<sec id="section3-2150135111420888">
<title>Decision Making With VAD Placement</title>
<sec id="section4-2150135111420888">
<title>What Patients Most Benefit From VAD Placement and When?</title>
<p>The decision to place a child on mechanical circulatory support is complex and should involve inputs from a multidisciplinary team including surgeon, intensivist, cardiologist, transplant specialist, and family. It is necessary to consider current outcomes of patients waiting on the heart transplant list and compare them with the most contemporary risks and benefits associated with long-term VAD use. In a study of outcomes of patients waiting on the heart transplant list, Almond et al found the overall wait list mortality to be 17%, but with tremendous variability based on patient-specific risk factors.<sup>
<xref ref-type="bibr" rid="bibr10-2150135111420888">10</xref>
</sup> For instance, a patient weighing greater than 10 kg, with a diagnosis of cardiomyopathy requiring inotropic support had a wait list mortality of 6%. If a patient with those same risk factors required mechanical ventilation, mortality increased to 29%. Patients weighing less than 10 kg, those with an underlying diagnosis of congenital heart disease, renal failure, and any patient requiring ECMO were at increased risk.</p>
<p>The reported mortality<sup>
<xref ref-type="bibr" rid="bibr4-2150135111420888">4</xref>,<xref ref-type="bibr" rid="bibr11-2150135111420888">11</xref>
<xref ref-type="bibr" rid="bibr12-2150135111420888"/>
<xref ref-type="bibr" rid="bibr13-2150135111420888"/>
<xref ref-type="bibr" rid="bibr14-2150135111420888"/>–<xref ref-type="bibr" rid="bibr15-2150135111420888">15</xref>
</sup> associated with pediatric VAD support varies from 12% to 32%. <xref ref-type="table" rid="table1-2150135111420888">Table 1</xref>
 lists the mortality rates of some of the largest pediatric series using the Berlin Heart Excor and/or Thoratec VAD. The ongoing Berlin Heart EXCOR IDE trial promises the most rigorous assessment of outcomes to date. Given the known risks of VAD therapy, it is reasonable to consider medical management, VAD, and ECMO as complementary therapies in the care of the pediatric patient with heart failure. Timing of VAD placement should emphasize the prevention of end-organ failure with the goal of long-term organ preservation and optimization of transplant candidacy. Therefore, we believe a VAD should be strongly considered in the patient on the heart transplant list with impending or existing organ failure secondary to heart failure. <xref ref-type="table" rid="table2-2150135111420888">Table 2</xref>
 compares the advantages and disadvantages of VAD and ECMO as mechanical support options, and <xref ref-type="table" rid="table3-2150135111420888">Table 3</xref>
 lists potential indications for VAD placement in patients listed for heart transplantation. Other indications for VAD placement include bridge to recovery or destination therapy.</p>
<table-wrap id="table1-2150135111420888" position="float">
<label>Table 1.</label>
<caption>
<p>Studies Reporting Pediatric VAD Mortality</p>
</caption>
<graphic alternate-form-of="table1-2150135111420888" xlink:href="10.1177_2150135111420888-table1.tif"/>
<table>
<thead>
<tr>
<th>Study</th>
<th>Device</th>
<th>Population</th>
<th>Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hetzer et al<sup>
<xref ref-type="bibr" rid="bibr11-2150135111420888">11</xref>
</sup> 2006</td>
<td>Berlin Heart</td>
<td>n = 68; 1990-2005</td>
<td>38%</td>
</tr>
<tr>
<td>Morales et al<sup>
<xref ref-type="bibr" rid="bibr12-2150135111420888">12</xref>
</sup> 2011</td>
<td>Berlin Heart</td>
<td>n = 73; 2000-2007</td>
<td>23%</td>
</tr>
<tr>
<td>Humpl et al<sup>
<xref ref-type="bibr" rid="bibr13-2150135111420888">13</xref>
</sup> 2010</td>
<td>Berlin Heart</td>
<td>n = 15; 2004-2008</td>
<td>13%</td>
</tr>
<tr>
<td>Reinhartz et al<sup>
<xref ref-type="bibr" rid="bibr14-2150135111420888">14</xref>
</sup> 2005</td>
<td>Thoratec VAD</td>
<td>n = 209; 1982-2005</td>
<td>32%</td>
</tr>
<tr>
<td>Blume et al<sup>
<xref ref-type="bibr" rid="bibr4-2150135111420888">4</xref>
</sup> 2006</td>
<td>Various</td>
<td>n = 99; 1999-2003</td>
<td>17%</td>
</tr>
<tr>
<td>Stein et al<sup>
<xref ref-type="bibr" rid="bibr15-2150135111420888">15</xref>
</sup> 2010</td>
<td>Various</td>
<td>n = 25; 1998-2007</td>
<td>26%</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-2150135111420888">
<p>Abbreviation: VAD, ventricular assist device.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table2-2150135111420888" position="float">
<label>Table 2.</label>
<caption>
<p>Comparison of VAD and ECMO</p>
</caption>
<graphic alternate-form-of="table2-2150135111420888" xlink:href="10.1177_2150135111420888-table2.tif"/>
<table>
<thead>
<tr>
<th align="left">VAD</th>
<th align="left">ECMO</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Mortality: 13%-38%</td>
<td align="left">Mortality: 39%-57%</td>
</tr>
<tr>
<td align="left">Stroke 15%-48%</td>
<td align="left">Stroke 13%-26%</td>
</tr>
<tr>
<td align="left">Long term</td>
<td align="left">Short term</td>
</tr>
<tr>
<td align="left">Ongoing organ recovery</td>
<td align="left">Limited organ recovery</td>
</tr>
<tr>
<td align="left">Requires transthoracic cannulation</td>
<td align="left">Cannulation may be percutaneous</td>
</tr>
<tr>
<td align="left">Mobility/rehabilitation potential</td>
<td align="left">Need for sedation, ventilation</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-2150135111420888">
<p>Abbreviations: VAD, ventricular assist device; ECMO, extracorporeal membrane oxygenation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="table3-2150135111420888" position="float">
<label>Table 3.</label>
<caption>
<p>Indications for Pediatric VAD Placement</p>
</caption>
<graphic alternate-form-of="table3-2150135111420888" xlink:href="10.1177_2150135111420888-table3.tif"/>
<table>
<thead>
<tr>
<th align="left" colspan="2">VAD may be considered in a pediatric patient who is listed for heart transplantation:</th>
</tr>
</thead>
<tbody>
<tr><td>1.</td><td>Requires ECMO</td></tr>
<tr><td>2.</td><td>Requires mechanical ventilation secondary to heart failure</td></tr>
<tr><td>3.</td><td>Fails inotrope wean with high inotrope requirement</td></tr>
<tr><td>4.</td><td>Demonstrates evidence of existing or impending end-organ failure (rising creatinine, hepatic function tests, etc)</td></tr>
<tr><td>5.</td><td>Growth failure and/or inability to tolerate feeds</td></tr>
<tr><td>6.</td><td>Bed rest or limitations of activities of daily living due to the degree of heart failure</td></tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn3-2150135111420888">
<p>Abbreviations: VAD, ventricular assist device; ECMO, extracorporeal membrane oxygenation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section5-2150135111420888">
<title>When is BiVAD Indicated?</title>
<p>There are no clear pediatric guidelines indicating which patients require BiVAD at the time of initial implantation, versus those who require only LVAD. Pulmonary hypertension has long been discussed as a risk factor for poor outcomes after heart transplantation and in particular those undergoing VAD placement. However, multiple case series have demonstrated good success in lowering pulmonary vascular resistance with left ventricular assist device (LVAD) alone, accompanied by good transplant outcomes.<sup>
<xref ref-type="bibr" rid="bibr16-2150135111420888">16</xref>
<xref ref-type="bibr" rid="bibr17-2150135111420888"/>–<xref ref-type="bibr" rid="bibr18-2150135111420888">18</xref>
</sup> Farrar et al found that patients requiring BiVAD placement in a large adult series were no more likely to have pulmonary hypertension than those requiring LVAD alone, but BiVAD patients were more severely ill with more advanced heart failure, as evidenced by a higher creatinine and bilirubin as well as a lower native cardiac index.<sup>
<xref ref-type="bibr" rid="bibr18-2150135111420888">18</xref>
</sup> While some argue for aggressive BiVAD placement due to its positive effects on the sequelae of right heart failure in the postoperative period, with the exception of some smaller single-center series, BiVAD placement has been associated with higher mortality.<sup>
<xref ref-type="bibr" rid="bibr11-2150135111420888">11</xref>,<xref ref-type="bibr" rid="bibr12-2150135111420888">12</xref>,<xref ref-type="bibr" rid="bibr18-2150135111420888">18</xref>
<xref ref-type="bibr" rid="bibr19-2150135111420888"/>
<xref ref-type="bibr" rid="bibr20-2150135111420888"/>–<xref ref-type="bibr" rid="bibr21-2150135111420888">21</xref>
</sup> While patient selection certainly plays a role in poor BiVAD outcomes, the use of BiVAD is associated with longer operative times, longer bypass times, and a higher incidence of postoperative bleeding. Therefore, BiVAD placement may be avoided by expeditious LVAD placement prior to development of organ failure. It is currently our practice in most cases to place an LVAD alone and aggressively manage right ventricular (RV) dysfunction in the operating room upon separation from bypass. If despite this approach RV failure remains problematic, a right ventricular assist device (RVAD) would be placed at that time.</p>
</sec>
</sec>
<sec id="section6-2150135111420888">
<title>Physiology of LVAD Support</title>
<p>Ideally, VAD placement results in volume and pressure unloading of the ailing myocardium, providing normal cardiac output and reducing venous congestion, leading to relief of symptoms of heart failure. This ideally facilitates full-organ recovery and physical rehabilitation. Placement of an LVAD creates a unique physiology wherein the LV and VAD chamber act in competition for preload and eject against the same afterload.<sup>
<xref ref-type="bibr" rid="bibr22-2150135111420888">22</xref>
</sup> The LV ideally functions as a passive conduit supplying preload to the device. The aortic valve should only eject when the systolic pressure within the LV chamber can overcome the afterload it is exposed to. When the LV is fully decompressed, this is unlikely to occur. If the LV is noted to be ejecting consistently, it may be undersupported, resulting in undesirable wall stress and delayed myocardial recovery. Alternatively, native ejection may be a sign of ventricular recovery and can be used to predict who will wean successfully.</p>
<p>The relationship of LVAD placement to RV function is perhaps more complex. The LVAD receives its inflow from the left heart and is therefore dependent on right heart and pulmonary vascular bed function for adequate preload of the device. Failure of RV in the setting of LVAD placement may result in underfilling of the device and symptoms of right heart failure. However, as discussed above, LVAD support results in a reduction of pulmonary capillary wedge pressure and pulmonary arterial pressure over time, improving pulmonary hypertension.<sup>
<xref ref-type="bibr" rid="bibr23-2150135111420888">23</xref>
</sup> Combined with the resolution of existing pulmonary edema, RV afterload should therefore decrease, improving RV ejection. Ventriculoventricular interactions are likely at play here as well: a fully decompressed LV will result in a midline septal position, thus maximizing RV efficiency and tricuspid valve function by eliminating annular strain on the tricuspid apparatus.</p>
<p>With the advent of third-generation axial flow devices, the debate regarding the systemic effects of pulsatile versus continuous flow has been revived. Axial, or continuous flow VADs, are smaller, with a more simplified design and less moving parts.<sup>
<xref ref-type="bibr" rid="bibr7-2150135111420888">7</xref>,<xref ref-type="bibr" rid="bibr8-2150135111420888">8</xref>
</sup> They offer the advantages of greater mobility, device durability, and lower anticoagulation requirements, all potentially improving survival and quality of life. Early experience has identified concerns specific to long-term axial flow device use, including increased vasoconstrictor needs at the time oftransplant attributed to adaptive changes in vascular tone with lowered systemic vascular resistance; changes in renal perfusion and the disruption of normal renin–angiotensin and norepinephrine responses; the finding of less effective LV unloading by echocardiography; and an increased incidence of significant gastrointestinal (GI) bleeding possibly associated with the development of GI arteriovenous malformations.<sup>
<xref ref-type="bibr" rid="bibr24-2150135111420888">24</xref>,<xref ref-type="bibr" rid="bibr25-2150135111420888">25</xref>
</sup> The impact of axial flow devices on survival and reduction in significant morbidities associated with VAD use in pediatrics is yet to be determined.</p>
</sec>
<sec id="section7-2150135111420888">
<title>Initial Postoperative Care</title>
<p>The therapeutic goals of initial ICU care are to (1) ensure appropriate device function; (2) establish adequate cardiac output, including support of RV function; (3) control postoperative bleeding; and (4) perform general postoperative care which includes optimization of ventilation and oxygenation, the empiric use of antibiotics, and the appropriate treatment of pain and anxiety. Typically the child returning from the operating room following LVAD placement will require intubation and mechanical ventilation, right heart support possibly including nitric oxide/vasopressors, and moderate-to-deep sedation until the above goals are achieved. Once stabilization has occurred and postoperative bleeding is controlled, patients should be weaned from mechanical ventilation and anticoagulation protocols initiated.</p>
<p>Ventricular assist device settings upon arrival to the ICU vary based on device manufacturer recommendations and patient physiology. The Thoratec VAD may be initially set in the asynchronous/fixed rate mode to accommodate swings in the loading conditions in the immediate postoperative period. This mode allows tight control over the device-supplied cardiac index, assuming complete ejection and filling: CI = Rate × Chamber Volume/BSA. Once the hemodynamic stability has been achieved, the volume mode is recommended to optimally unload the right heart while providing the maximum amount of cardiac output. The Berlin Heart EXCOR VAD allows only a fixed rate mode. Once stable settings are established and the VAD is functioning well, care in the ICU should be focused on manipulating the loading conditions to the VAD, rather than the VAD settings themselves. <xref ref-type="table" rid="table4-2150135111420888">Table 4</xref>
 outlines common troubleshooting scenarios in the post-operative period, which are reviewed in detail below.</p>
<table-wrap id="table4-2150135111420888" position="float">
<label>Table 4.</label>
<caption>
<p>Postoperative ICU Device Troubleshooting</p>
</caption>
<graphic alternate-form-of="table4-2150135111420888" xlink:href="10.1177_2150135111420888-table4.tif"/>
<table>
<thead>
<tr>
<th align="left">Problem</th>
<th align="left">Etiology</th>
<th align="left">Intervention</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left">Inadequate Filling</td>
<td align="left">Decreased preload</td>
<td align="left">General: lowering VAD rate and increasing diastolic filling time may temporarily improve filling; increase negative pressure</td>
</tr>
<tr>
<td align="left">
</td>
<td align="left" rowspan="3">
<list list-type="simple">
<list-item>
<p>Hypovolemia</p>
</list-item>
<list-item>
<p>RV Failure</p>
</list-item>
<list-item>
<p>Pulmonary HTN</p>
</list-item>
</list>
</td>
<td align="left" rowspan="3">
<list list-type="simple">
<list-item>
<p>Titrate volume to goal output and complete filling;</p>
</list-item>
<list-item>
<p>Titrate inotropes to goal output; decrease RV afterload;</p>
</list-item>
<list-item>
<p>Lower PVR: optimize ventilation, treat atelectasis and effusions, avoid overdistension; milrinone; inhaled nitric oxide; oxygen</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td align="left">
</td>
</tr>
<tr>
<td align="left">
</td>
</tr>
<tr>
<td align="left">Incomplete Ejection</td>
<td align="left">Elevated afterload</td>
<td align="left">Maintain VAD driving pressure 100 mmHG greater than SBP</td>
</tr>
<tr>
<td align="left">
</td>
<td align="left" rowspan="2">
<list list-type="simple">
<list-item>
<p>Pain/anxiety</p>
</list-item>
<list-item>
<p>Elevated SVR</p>
</list-item>
</list>
</td>
<td align="left" rowspan="2">
<list list-type="simple">
<list-item>
<p>Provide sedation/analgesia;</p>
</list-item>
<list-item>
<p>Milrinone, nitroprusside, nicardipine</p>
</list-item>
</list>
</td>
</tr>
<tr>
<td align="left">
</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn4-2150135111420888">
<p>Abbreviations: RV, right ventricle; HTN, hypertension; PVR, pulmonary vascular resistance; SBP, systolic blood pressure; SVR, systemic vascular resistance.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section8-2150135111420888">
<title>Postoperative Troubleshooting</title>
<p>Right ventricular dysfunction and postoperative bleeding are the most common early problems managed in the ICU following VAD placement and are interrelated. Right ventricular failure may result in elevated central venous pressure and hepatic congestion, as well as ascites and protein loss, all of which contribute to coagulopathy. Bleeding requires blood and factor replacement, which may result in further volume loading a dysfunctional RV. In addition, troubleshooting VAD problems in the early postoperative phase is reviewed.</p>
</sec>
<sec id="section9-2150135111420888">
<title>Support of the RV</title>
<p>Prior to implantation, the suitability of the RV to support the cardiac output postimplant must be assessed. If a decision to pursue LVAD is made, the need for aggressive medical management of RV dysfunction should be anticipated. This includes augmenting RV function via the titration of inotropes, aggressive treatment of postoperative bleeding, targeting a low normal CVP, avoiding volume overload and distension of the RV, minimizing elevations in pulmonary vascular resistance by ventilating to a normal functional residual capacity and utilizing milrinone and nitric oxide, correcting acidosis and hypocalcemia, ensuring adequate decompression of the left heart with commensurate fall in left atrial and pulmonary arterial pressures, and treatment of arrhythmias. Extubation should be pursued as soon as it is safe and reasonable, as positive pressure ventilation may be deleterious for a failing RV.</p>
</sec>
<sec id="section10-2150135111420888">
<title>Control of Postoperative Bleeding</title>
<p>Bleeding is the most common problem in the immediate postoperative period, resulting in reoperation in 14% to 60% of patients.<sup>
<xref ref-type="bibr" rid="bibr18-2150135111420888">18</xref>,<xref ref-type="bibr" rid="bibr26-2150135111420888">26</xref>
</sup> Significant bleeding is more likely to occur in patients with preoperative higher severity of illness, patients requiring BiVAD, patients with hepatic and/or renal failure, patients on ECMO, patients requiring anticoagulation preoperatively, and patients with a history of previous thoracotomy. Platelet function is altered in the postoperative period by cardiopulmonary bypass and via interaction with VAD components. In addition, red blood cells experience shear stress and hemolysis with exposure to mechanical support systems. Liver dysfunction and acquired depletion of von Willebrand factor also contributes to bleeding complications in the postoperative period.<sup>
<xref ref-type="bibr" rid="bibr24-2150135111420888">24</xref>,<xref ref-type="bibr" rid="bibr26-2150135111420888">26</xref>,<xref ref-type="bibr" rid="bibr27-2150135111420888">27</xref>
</sup>
</p>
<p>Although blood product administration is typically much lower when compared with ECMO, it is particularly problematic for the VAD patient due to its effects on right heart function, pulmonary vascular congestion, infection and immune dysfunction, and allosensitization.<sup>
<xref ref-type="bibr" rid="bibr28-2150135111420888">28</xref>
</sup> Therefore, every effort should be made in the first 24 hours to reduce postoperative bleeding. Anticoagulation protocols should not start until surgical bleeding has resolved. Measures may be taken in the preoperative phase to reduce bleeding complications: anticoagulants should be stopped, coagulation profiles should be optimized, and other medications impacting coagulation such as H2 blockers should be stopped.<sup>
<xref ref-type="bibr" rid="bibr26-2150135111420888">26</xref>
</sup> Once the patient separates from bypass, heparin should be fully reversed and aggressive monitoring and replacement of clotting factors should occur. Upon arrival to the ICU, an initial set of hematologic parameters should be checked, followed by repeat testing until resolution of coagulopathy. Thromboelastography ([TEG], Skokie, Illinois) may aid in the determination of platelet function. If the patient continues to bleed despite correction of laboratory markers, surgical exploration should be considered.</p>
</sec>
<sec id="section11-2150135111420888">
<title>Problem: Inadequate Filling</title>
<p>Inadequate filling is a common problem in the immediate postoperative period and may be related to the device or the patient. In the Thoratec VAD volume mode, the device will slow to allow more complete filling and set off a device alarm if the rate slows below an adjustable set point. In the Berlin Heart EXCOR, inspection of the device chamber will reveal inadequate diastolic filling with wrinkling of the membrane. Poor filling may result from low preload to the VAD due to pulmonary hypertension, RV failure, or pulmonary pathology such as atelectasis, tamponade due to pericardial effusion, hemothorax or pneumothorax, systemic vasodilation due to medications, systemic inflammatory response syndrome, or sepsis, or obstruction to the inflow cannula. Echocardiography and intracardiac pressure measurements in the ICU can help triage this problem. A computed tomography scan of the chest may be indicated if tamponade due to hemothorax is suspected. When treatment of patient-related factors prove unsuccessful, adjustments to the VAD settings may improve filling, including increasing the negative pressure, decreasing the percentage of systole (increasing time spent filling the device during diastole), and temporarily slowing the VAD rate.</p>
</sec>
<sec id="section12-2150135111420888">
<title>Problem: Incomplete Ejection</title>
<p>Incomplete ejection may be more detrimental as it promotes stasis in the device and increases the risk of clot formation in addition to limiting cardiac output. This problem is most commonly related to a high afterload state in the patient. High afterload may be a result of elevated systemic vascular resistance, cannula obstruction from clot or external compression, or patient positioning, leading to kinking of the cannula. Medical management of elevated systemic vascular resistance centers on treatment of pain and anxiety, and pharmacologic lowering of systemic afterload via vasodilators. Care must be taken to maintain an adequate VAD systolic ejection force above the arterial pressure or incomplete ejection will result. In most cases, the drive pressure should be maintained at least 100 mm Hg above the systolic blood pressure.</p>
</sec>
<sec id="section13-2150135111420888">
<title>Problem: Cyanosis and/or Respiratory Failure</title>
<p>In rare cases, parenchymal lung disease may be significant enough to prohibit adequate oxygenation and ventilation in the postoperative period. In the most severe cases, ECMO may be used temporarily to support these functions. In the case of cyanosis without respiratory failure, the presence of a patent foramen ovale creating a right-to-left shunt must be considered. Any identifiable right-to-left shunt should be closed at the time of VAD implantation, given the potential to alter VAD functioning and the heightened risk of air (or thrombotic) embolus in the presence of a negative pressure in the LV chamber.</p>
</sec>
</sec>
<sec id="section14-2150135111420888">
<title>Long-Term Care in the ICU and Adverse Events</title>
<p>Following initial stabilization, goals of the ICU shifts to achieving organ recovery and rehabilitation. An anticoagulation protocol should be initiated once the initial postoperative bleeding is controlled. Acquired comorbidities such as respiratory, renal, or neurologic failure may continue to require ICU level care as these other processes move forward. Renal failure is a particularly important comorbidity, as patients who meet established criteria for renal failure and those who require dialysis are at particularly high risk during VAD support and at the time of eventual transplantation.<sup>
<xref ref-type="bibr" rid="bibr15-2150135111420888">15</xref>
</sup>
</p>
<p>Understanding the incidence and pattern of adverse events during VAD support will help in developing management strategies to prevent their occurrence and monitor for their early detection. In a review utilizing the International Registry for Mechanically Assisted Circulatory Support (INTERMACS) definitions for morbidity, Genovese et al found that 174 (89%) of 195 adult patients had at least one significant adverse event during VAD support, with the most common events being bleeding (48%), infection (42%), arrhythmias (36%), tamponade (28%), respiratory events (24%), neurologic events (24%), and reoperations (31%).<sup>
<xref ref-type="bibr" rid="bibr29-2150135111420888">29</xref>
</sup> In addition the time course of these complications demonstrated a steep rise in most categories of adverse events during the first 5 to 10 days, with a leveling out of adverse event rates from 30 to 60 days. Notably, clotting, neurologic injury, and device failure occur with significant frequency throughout the period of VAD support. Stein et al<sup>
<xref ref-type="bibr" rid="bibr15-2150135111420888">15</xref>
</sup> applied the INTERMACS criteria to 24 pediatric patients at Stanford, utilizing various devices, and found significantly higher morbidity rates than previously published series, with a greater than 50% incidence of respiratory failure, major localized infection, major bleeding events, hepatic dysfunction, and right failure. In addition, cerebrovascular accidents were found in 48% of patients. The authors note that the application of standardized criteria such as INTERMACS should eliminate variable reporting of morbidity existing in many single-center series and should be used going forward when reporting results to allow accurate comparison.</p>
<p>Bleeding continues to be a problem outside of the immediate postimplant period, although major bleeding is relatively rare.<sup>
<xref ref-type="bibr" rid="bibr24-2150135111420888">24</xref>,<xref ref-type="bibr" rid="bibr29-2150135111420888">29</xref>
</sup> The incidence of life-threatening thrombosis or stroke continues at a steady rate for the duration of VAD support, and monitoring for thrombosis formation in the device is critical. Loss of a flash when shining a light through the top of the Thoratec VAD fluid chamber may indicate thrombus formation. The Berlin Heart is designed to readily allow visual inspection; small fibrin deposits (white or tan) and organized thrombus (dark red or black) can be seen within the blood chamber or on the valves themselves. The decision to change a pump is a difficult one, and the risks of potential embolization must be seriously weighed against the period of hemodynamic vulnerability which may occur during a blood pump change.</p>
<p>Long-term anticoagulation goals vary by device and institution. For the most part, anticoagulation is initially achieved with unfractionated heparin within 72 hours of implant when surgical bleeding has diminished. Transition to various combinations of aspirin, warfarin, and dipyridamole are advocated.<sup>
<xref ref-type="bibr" rid="bibr30-2150135111420888">30</xref>
<xref ref-type="bibr" rid="bibr31-2150135111420888"/>–<xref ref-type="bibr" rid="bibr32-2150135111420888">32</xref>
</sup> Low-molecular-weight heparin has also been used with good success.<sup>
<xref ref-type="bibr" rid="bibr33-2150135111420888">33</xref>
</sup> Regardless of anticoagulation protocol, accurate monitoring of the patients hematologic state is paramount. We typically monitor heparin levels at least daily while on heparin, prothrombin time/international normalized ratio (PT/INR) daily while on Coumadin, and TEG with platelet mapping daily to monitor the platelet effect of aspirin and dipyidamole. Once a stable regimen is achieved, monitoring laboratories can be spread out to one to two times per week but should be rechecked with any change in patient condition or medications which may affect metabolism.</p>
<p>Neurologic events are perhaps the most devastating for patients, families, and staff. They can occur at any time during VAD support, and their incidence and severity varies depending on device and patient factors such as age and severity of illness. In their early experience, Reinhartz et al found that 15 (27%) of 35 pediatric patients with a Thoratec had a major neurologic complication, with 6 deaths.<sup>
<xref ref-type="bibr" rid="bibr14-2150135111420888">14</xref>
</sup> The authors concluded that left atrial cannulation was a risk factor in these cases. Genovese et al found a 25% incidence of neurologic injury in their adult study, with 15% infarct or cerebrovascular accident.<sup>
<xref ref-type="bibr" rid="bibr29-2150135111420888">29</xref>
</sup> Tsukui et al documented a 25% incidence of cerebrovascular accident in long-term VAD use in adults, with infection and length of support risk factors for brain injury.<sup>
<xref ref-type="bibr" rid="bibr34-2150135111420888">34</xref>
</sup> Monitoring for neurologic injury can be challenging; as they may occur as acute events with little warning. Subtle signs such as evidence of thrombosis formation within the device, change in mental status, and any change in the neurologic examination should trigger an aggressive evaluation for potential neurologic injury. Head ultrasounds may be helpful in infants, but computed tomography examinations of the head should be undertaken in older children and when ultrasounds are inconclusive. If the degree of suspicion is high enough, anticoagulation should be stopped until intracranial pathology can be ruled out; and in severe cases requiring hematoma evacuation or intracranial pressure monitoring, anticoagulation can be reversed. Investigators are currently assessing the role of biomarkers of brain injury for detection of neurologic injury in pediatric mechanical support, and this may prove to be an important early warning system in the future.<sup>
<xref ref-type="bibr" rid="bibr35-2150135111420888">35</xref>
</sup>
</p>
<p>Infection is an important modifiable complication of VAD placement. Patients are at risk due to severity of illness, suppression of immune function, and an intense level of monitoring with indwelling catheters.<sup>
<xref ref-type="bibr" rid="bibr29-2150135111420888">29</xref>
</sup> In the chronic phase, wound, driveline, and device infections do occur and should be treated aggressively.<sup>
<xref ref-type="bibr" rid="bibr36-2150135111420888">36</xref>,<xref ref-type="bibr" rid="bibr37-2150135111420888">37</xref>
</sup> Gastrointestinal complications occur for a variety of reasons, including bleeding or infection related to cannula sites, GI bleeding, and bowel edema secondary to ongoing right heart failure.<sup>
<xref ref-type="bibr" rid="bibr24-2150135111420888">24</xref>,<xref ref-type="bibr" rid="bibr38-2150135111420888">38</xref>,<xref ref-type="bibr" rid="bibr39-2150135111420888">39</xref>
</sup> A distinct advantage of VADs as a mechanical support system is the emphasis on physical and nutritional rehabilitation. Nutritional rehabilitation is an important factor in wound healing and organ recovery in the postoperative phase. Aggressive nutrition support is extremely important in the recovery of the postoperative VAD patient and should include involvement of nutrition experts.</p>
</sec>
<sec id="section15-2150135111420888">
<title>Challenging Scenarios in ICU Management</title>
<sec id="section16-2150135111420888">
<title>Aortic Insufficiency</title>
<p>The presence of aortic insufficiency can significantly limit the effectiveness of VAD therapy. While some patients, especially in the adult population, may have preexisting aortic insufficiency, others may develop it on mechanical support. This may result from mechanical stress to the valve annulus from cannula position or more commonly due to acute changes in the loading conditions across the valve as the pressure within the ventricular cavity decreases while simultaneously increasing the afterload in the ascending aorta. When identified preoperatively, aortic insufficiency can be successfully intervened upon at the time of cannulation.<sup>
<xref ref-type="bibr" rid="bibr40-2150135111420888">40</xref>
<xref ref-type="bibr" rid="bibr41-2150135111420888"/>–<xref ref-type="bibr" rid="bibr42-2150135111420888">42</xref>
</sup> This strategy in effect eliminates the potential of using the VAD as bridge to recovery, unless a valve repair or replacement is undertaken prior to weaning. When aortic insufficiency is identified after VAD placement, the severity of the insufficiency must be weighed against the additional operative morbidity involved.</p>
</sec>
<sec id="section17-2150135111420888">
<title>Mechanical Support of the Failing Single Ventricle</title>
<p>Effective mechanical support may be challenging in patients with single-ventricle anatomy. Although initially considered a relative contraindication, recent reports have shown better outcomes with ECMO support in the postoperative Norwood patient.<sup>
<xref ref-type="bibr" rid="bibr43-2150135111420888">43</xref>,<xref ref-type="bibr" rid="bibr44-2150135111420888">44</xref>
</sup> However, the Glenn and Fontan patient have continued to have low survival when ECMO support is required.<sup>
<xref ref-type="bibr" rid="bibr45-2150135111420888">45</xref>
</sup> Given the increasing numbers of single-ventricle patients at risk of heart failure, researchers have focused on developing more effective mechanical support strategies for these patients, including modifying existing VADs and developing novel methods such as indwelling blood pumps which could augment flow in the Fontan pathway.<sup>
<xref ref-type="bibr" rid="bibr46-2150135111420888">46</xref>,<xref ref-type="bibr" rid="bibr47-2150135111420888">47</xref>
</sup>
</p>
<p>In the patient with a superior cavopulmonary anastomosis (Glenn, Hemi-Fontan), reports of successful VAD support can be found in the literature, although the experience remains small.<sup>
<xref ref-type="bibr" rid="bibr48-2150135111420888">48</xref>,<xref ref-type="bibr" rid="bibr49-2150135111420888">49</xref>
</sup> Due to the separation of the superior and inferior venous return, adequate decompression of the Glenn circuit depends on passive flow through the pulmonary vascular bed. If this decompression is ineffective, it may result in diminished cardiac output, cyanosis, and elevated superior vena cava pressure. Given the known neurologic complications of mechanical support, the elevation of superior vena cava pressure is of particular concern. Glenn takedown to an aortopulmonary shunt should be considered in the setting of severe heart failure and may facilitate mechanical support if needed.<sup>
<xref ref-type="bibr" rid="bibr50-2150135111420888">50</xref>
</sup> Various strategies of cannulation of the Fontan patient have been described, including single ventricle to aortic cannulation with dependence on passive pulmonary blood flow, BiVAD placement utilizing the Fontan as a pulmonary ventricle, and isolated RVAD support of the Fontan circulation.<sup>
<xref ref-type="bibr" rid="bibr51-2150135111420888">51</xref>,<xref ref-type="bibr" rid="bibr52-2150135111420888">52</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section18-2150135111420888">
<title>Conclusion</title>
<p>Tremendous progress in VAD development, expanding indications, and increasing demand make intensive care of the VAD patient a growing area in the care of the pediatric heart failure patient. An understanding of the indications, complications, and the physiologic interplay between device and patient are necessary to adequately care for VAD patients in the perioperative period. Effective medical management of RV failure, bleeding, and the prevention of complications requires a collaborative, multidisciplinary approach. The complex anatomy of the congenital heart disease population continues to pose challenges for mechanical support systems and is an area of continued development.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-2150135111420888">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-2150135111420888">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="other" id="fn3-2150135111420888">
<p>Presented at the Seventh International Conference on Pediatric Mechanical Circulatory Support Systems and Pediatric Cardiopulmonary Perfusion, Philadelphia, USA; May 5-7, 2011.</p>
</fn>
</fn-group>
<glossary content-type="abbr">
<title>Acronyms and Abbreviations</title>
<def-list>
<def-item>
<term id="term1-2150135111420888">BiVAD</term>
<def>
<p>biventricular assist device</p>
</def>
</def-item>
<def-item>
<term id="term2-2150135111420888">BSA</term>
<def>
<p>body surface area (m<sup>2</sup>)</p>
</def>
</def-item>
<def-item>
<term id="term3-2150135111420888">ECMO</term>
<def>
<p>extracorporeal membrane oxygenation</p>
</def>
</def-item>
<def-item>
<term id="term4-2150135111420888">GI</term>
<def>
<p>gastrointestinal</p>
</def>
</def-item>
<def-item>
<term id="term5-2150135111420888">ICU</term>
<def>
<p>intensive care unit</p>
</def>
</def-item>
<def-item>
<term id="term6-2150135111420888">INR</term>
<def>
<p>international normalized ratio</p>
</def>
</def-item>
<def-item>
<term id="term7-2150135111420888">INTERMACS</term>
<def>
<p>International Registry for Mechanically Assisted Circulatory Support</p>
</def>
</def-item>
<def-item>
<term id="term8-2150135111420888">LVAD</term>
<def>
<p>left ventricular assist device</p>
</def>
</def-item>
<def-item>
<term id="term9-2150135111420888">RVAD</term>
<def>
<p>right ventricular assist device</p>
</def>
</def-item>
<def-item>
<term id="term10-2150135111420888">PT</term>
<def>
<p>prothrombin time</p>
</def>
</def-item>
<def-item>
<term id="term11-2150135111420888">TEG</term>
<def>
<p>thromboelastography</p>
</def>
</def-item>
<def-item>
<term id="term12-2150135111420888">VAD</term>
<def>
<p>ventricular assist device</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="bibr1-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stiller</surname><given-names>B</given-names></name><name><surname>Hetzer</surname><given-names>R</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>Heart transplantation in children after mechanical circulatory support with pulsatile pneumatic assist device</article-title>. <source>J Heart Lung Transplant</source>. <year>2003</year>;<volume>22</volume>(<issue>11</issue>):<fpage>1201</fpage>–<lpage>1208</lpage>.</citation></ref>
<ref id="bibr2-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>del Nido</surname><given-names>PJ</given-names></name><name><surname>Armitage</surname><given-names>JM</given-names></name><name><surname>Fricker</surname><given-names>FJ</given-names></name><etal/></person-group>. <article-title>Extracorporeal membrane oxygenation support as a bridge to pediatric heart transplantation</article-title>. <source>Circulation</source>. <year>1994</year>;<volume>90</volume>(<issue>5 pt 2</issue>):<fpage>II66</fpage>–<lpage>II69</lpage>.</citation></ref>
<ref id="bibr3-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gajarski</surname><given-names>RJ</given-names></name><name><surname>Mosca</surname><given-names>RS</given-names></name><name><surname>Ohye</surname><given-names>RG</given-names></name><etal/></person-group> <article-title>Use of extracorporeal life support as a bridge to pediatric cardiac transplantation</article-title>. <source>J Heart Lung Transplant</source>. <year>2003</year>;<volume>22</volume>(<issue>1</issue>):<fpage>28</fpage>–<lpage>34</lpage>.</citation></ref>
<ref id="bibr4-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blume</surname><given-names>ED</given-names></name><name><surname>Naftel</surname><given-names>DC</given-names></name><name><surname>Bastardi</surname><given-names>HJ</given-names></name><name><surname>Duncan</surname><given-names>BW</given-names></name><name><surname>Kirklin</surname><given-names>JK</given-names></name><name><surname>Webber</surname><given-names>SA</given-names></name></person-group>. <article-title>Outcomes of children bridged to heart transplantation with ventricular assist devices: a multi-institutional study</article-title>. <source>Circulation</source>. <year>2006</year>;<volume>113</volume>(<issue>19</issue>):<fpage>2313</fpage>–<lpage>2319</lpage>.</citation></ref>
<ref id="bibr5-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>DL</given-names></name><name><surname>Zafar</surname><given-names>F</given-names></name><name><surname>Rossano</surname><given-names>JW</given-names></name><etal/></person-group> <article-title>Use of ventricular assist devices in children across the United States: analysis of 7.5 million pediatric hospitalizations</article-title>. <source>Ann Thorac Surg</source>. <year>2010</year>;<volume>90</volume>(<issue>4</issue>):<fpage>1313</fpage>–<lpage>1318</lpage>.</citation></ref>
<ref id="bibr6-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Baldwin</surname><given-names>JT</given-names></name><name><surname>Borovetz</surname><given-names>HS</given-names></name><name><surname>Duncan</surname><given-names>BW</given-names></name><name><surname>Gartner</surname><given-names>MJ</given-names></name><name><surname>Jarvik</surname><given-names>RK</given-names></name><name><surname>Weiss</surname><given-names>WJ</given-names></name></person-group>. <article-title>The national heart, lung, and blood institute pediatric circulatory support program: a summary of the 5-year experience</article-title>. <source>Circulation</source>. <year>2011</year>;<volume>123</volume>(<issue>11</issue>):<fpage>1233</fpage>–<lpage>1240</lpage>.</citation></ref>
<ref id="bibr7-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Owens</surname><given-names>WR</given-names></name><name><surname>Bryant</surname><given-names>R III</given-names></name><name><surname>Dreyer</surname><given-names>WJ</given-names></name><name><surname>Price</surname><given-names>JF</given-names></name><name><surname>Morales</surname><given-names>DL</given-names></name></person-group>. <article-title>Initial clinical experience with the HeartMate II ventricular assist system in a pediatric institution</article-title>. <source>Artif Organs</source>. <year>2010</year>;<volume>34</volume>(<issue>7</issue>):<fpage>600</fpage>–<lpage>603</lpage>.</citation></ref>
<ref id="bibr8-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Frazier</surname><given-names>OH</given-names></name><name><surname>Rose</surname><given-names>EA</given-names></name><name><surname>Oz</surname><given-names>MC</given-names></name><etal/></person-group> <article-title>Multicenter</article-title> <article-title>clinical evaluation of the HeartMate vented electric left ventricular assist system in patients awaiting heart transplantation</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2001</year>;<volume>122</volume>(<issue>6</issue>):<fpage>1186</fpage>–<lpage>1195</lpage>.</citation></ref>
<ref id="bibr9-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>JD</given-names></name><name><surname>Reinhartz</surname><given-names>O</given-names></name></person-group>. <article-title>Clinical outcomes in pediatric patients implanted with Thoratec ventricular assist device</article-title>. <source>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</source>. <year>2006</year>;<volume>9</volume>(<issue>1</issue>):<fpage>115</fpage>–<lpage>122</lpage>.</citation></ref>
<ref id="bibr10-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almond</surname><given-names>CS</given-names></name><name><surname>Thiagarajan</surname><given-names>RR</given-names></name><name><surname>Piercey</surname><given-names>GE</given-names></name><etal/></person-group> <article-title>Waiting list mortality among children listed for heart transplantation in the United States</article-title>. <source>Circulation</source>. <year>2009</year>;<volume>119</volume>(<issue>5</issue>):<fpage>717</fpage>–<lpage>727</lpage>.</citation></ref>
<ref id="bibr11-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hetzer</surname><given-names>R</given-names></name><name><surname>Alexi-Meskishvili</surname><given-names>V</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><etal/></person-group> <article-title>Mechanical cardiac support in the young with the Berlin Heart EXCOR pulsatile ventricular assist device: 15 years’experience</article-title>. <source>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</source>. <year>2006</year>;<volume>9</volume>(<issue>1</issue>):<fpage>99</fpage>–<lpage>108</lpage>.</citation></ref>
<ref id="bibr12-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morales</surname><given-names>DL</given-names></name><name><surname>Almond</surname><given-names>CS</given-names></name><name><surname>Jaquiss</surname><given-names>RD</given-names></name><etal/></person-group> <article-title>Bridging children of all sizes to cardiac transplantation: the initial multicenter North American experience with the Berlin Heart EXCOR ventricular assist device</article-title>. <source>J Heart Lung Transplant</source>. <year>2011</year>;<volume>30</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>8</lpage>.</citation></ref>
<ref id="bibr13-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Humpl</surname><given-names>T</given-names></name><name><surname>Furness</surname><given-names>S</given-names></name><name><surname>Gruenwald</surname><given-names>C</given-names></name><name><surname>Hyslop</surname><given-names>C</given-names></name><name><surname>Van</surname><given-names>AG</given-names></name></person-group>. <article-title>The Berlin Heart EXCOR pediatrics-the sickkids experience 2004-2008</article-title>. <source>Artif Organs</source>. <year>2010</year>;<volume>34</volume>(<issue>12</issue>):<fpage>1082</fpage>–<lpage>1086</lpage>.</citation></ref>
<ref id="bibr14-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reinhartz</surname><given-names>O</given-names></name><name><surname>Hill</surname><given-names>JD</given-names></name><name><surname>Al-Khaldi</surname><given-names>A</given-names></name><name><surname>Pelletier</surname><given-names>MP</given-names></name><name><surname>Robbins</surname><given-names>RC</given-names></name><name><surname>Farrar</surname><given-names>DJ</given-names></name></person-group>. <article-title>Thoratec ventricular assist devices in pediatric patients: update on clinical results</article-title>. <source>ASAIO J</source>. <year>2005</year>;<volume>51</volume>(<issue>5</issue>):<fpage>501</fpage>–<lpage>503</lpage>.</citation></ref>
<ref id="bibr15-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>ML</given-names></name><name><surname>Robbins</surname><given-names>R</given-names></name><name><surname>Sabati</surname><given-names>AA</given-names></name><etal/></person-group> <article-title>Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS)-defined morbidity and mortality associated with pediatric ventricular assist device support at a single US center: the Stanford experience</article-title>. <source>Circ Heart Fail</source>. <year>2010</year>;<volume>3</volume>(<issue>6</issue>):<fpage>682</fpage>–<lpage>688</lpage>.</citation></ref>
<ref id="bibr16-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gallagher</surname><given-names>RC</given-names></name><name><surname>Kormos</surname><given-names>RL</given-names></name><name><surname>Gasior</surname><given-names>T</given-names></name><name><surname>Murali</surname><given-names>S</given-names></name><name><surname>Griffith</surname><given-names>BP</given-names></name><name><surname>Hardesty</surname><given-names>RL</given-names></name></person-group>. <article-title>Univentricular support results in reduction of pulmonary resistance and improved right ventricular function</article-title>. <source>ASAIO Trans</source>. <year>1991</year>;<volume>37</volume>(<issue>3</issue>):<fpage>M287</fpage>–<lpage>M288</lpage>.</citation></ref>
<ref id="bibr17-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haddad</surname><given-names>H</given-names></name><name><surname>Elabbassi</surname><given-names>W</given-names></name><name><surname>Moustafa</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Left ventricular assist devices as bridge to heart transplantation in congestive heart failure with pulmonary hypertension</article-title>. <source>ASAIO J</source>. <year>2005</year>;<volume>51</volume>(<issue>4</issue>):<fpage>456</fpage>–<lpage>460</lpage>.</citation></ref>
<ref id="bibr18-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farrar</surname><given-names>DJ</given-names></name><name><surname>Hill</surname><given-names>JD</given-names></name><name><surname>Pennington</surname><given-names>DG</given-names></name><etal/></person-group> <article-title>Preoperative and postoperative comparison of patients with univentricular and biventricular support with the thoratec ventricular assist device as a bridge to cardiac transplantation</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>1997</year>;<volume>113</volume>(<issue>1</issue>):<fpage>202</fpage>–<lpage>209</lpage>.</citation></ref>
<ref id="bibr19-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gandhi</surname><given-names>SK</given-names></name><name><surname>Huddleston</surname><given-names>CB</given-names></name><name><surname>Balzer</surname><given-names>DT</given-names></name><name><surname>Epstein</surname><given-names>DJ</given-names></name><name><surname>Boschert</surname><given-names>TA</given-names></name><name><surname>Canter</surname><given-names>CE</given-names></name></person-group>. <article-title>Biventricular assist devices as a bridge to heart transplantation in small children</article-title>. <source>Circulation</source>. <year>2008</year>;<volume>118</volume>(<issue>14 suppl</issue>):<fpage>S89</fpage>–<lpage>S93</lpage>.</citation></ref>
<ref id="bibr20-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dickerson</surname><given-names>HA</given-names></name><name><surname>Chang</surname><given-names>AC</given-names></name></person-group>. <article-title>Perioperative management of ventricular assist devices in children and adolescents</article-title>. <source>Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu</source>. <year>2006</year>;<volume>9</volume>(<issue>1</issue>):<fpage>128</fpage>–<lpage>139</lpage>.</citation></ref>
<ref id="bibr21-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mossad</surname><given-names>EB</given-names></name><name><surname>Motta</surname><given-names>P</given-names></name><name><surname>Rossano</surname><given-names>J</given-names></name><name><surname>Hale</surname><given-names>B</given-names></name><name><surname>Morales</surname><given-names>DL</given-names></name></person-group>. <article-title>Perioperative management of pediatric patients on mechanical cardiac support</article-title>. <source>Paediatr Anaesth</source>. <year>2011</year>;<volume>21</volume>(<issue>5</issue>):<fpage>585</fpage>–<lpage>593</lpage>.</citation></ref>
<ref id="bibr22-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mudge</surname><given-names>GH</given-names><suffix>Jr</suffix></name><name><surname>Fang</surname><given-names>JC</given-names></name><name><surname>Smith</surname><given-names>C</given-names></name><name><surname>Couper</surname><given-names>G</given-names></name></person-group>. <article-title>The physiologic basis for the management of ventricular assist devices</article-title>. <source>Clin Cardiol</source>. <year>2006</year>;<volume>29</volume>(<issue>7</issue>):<fpage>285</fpage>–<lpage>289</lpage>.</citation></ref>
<ref id="bibr23-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pavie</surname><given-names>A</given-names></name><name><surname>Leger</surname><given-names>P</given-names></name></person-group>. <article-title>Physiology of univentricular versus biventricular support</article-title>. <source>Ann Thorac Surg</source>. <year>1996</year>;<volume>61</volume>(<issue>1</issue>):<fpage>347</fpage>–<lpage>349</lpage>.</citation></ref>
<ref id="bibr24-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crow</surname><given-names>S</given-names></name><name><surname>John</surname><given-names>R</given-names></name><name><surname>Boyle</surname><given-names>A</given-names></name><etal/></person-group> <article-title>Gastrointestinal bleeding rates in recipients of nonpulsatile and pulsatile left ventricular assist devices</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2009</year>;<volume>137</volume>(<issue>1</issue>):<fpage>208</fpage>–<lpage>215</lpage>.</citation></ref>
<ref id="bibr25-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drews</surname><given-names>T</given-names></name><name><surname>Jurmann</surname><given-names>M</given-names></name><name><surname>Michael</surname><given-names>D</given-names></name><name><surname>Miralem</surname><given-names>P</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>Hetzer</surname><given-names>R</given-names></name></person-group>. <article-title>Differences in pulsatile and non-pulsatile mechanical circulatory support in long-term use</article-title>. <source>J Heart Lung Transplant</source>. <year>2008</year>;<volume>27</volume>(<issue>10</issue>):<fpage>1096</fpage>–<lpage>1101</lpage>.</citation></ref>
<ref id="bibr26-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>DJ</given-names></name><name><surname>Beauford</surname><given-names>RB</given-names></name></person-group>. <article-title>Left ventricular assist devices and bleeding: adding insult to injury</article-title>. <source>Ann Thorac Surg</source>. <year>2003</year>;<volume>75</volume>(<issue>6 suppl</issue>):<fpage>S42</fpage>–<lpage>S47</lpage>.</citation></ref>
<ref id="bibr27-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Uriel</surname><given-names>N</given-names></name><name><surname>Pak</surname><given-names>SW</given-names></name><name><surname>Jorde</surname><given-names>UP</given-names></name><etal/></person-group> <article-title>Acquired von Willebrand syndrome after continuous-flow mechanical device support contributes to a high prevalence of bleeding during long-term support and at the time of transplantation</article-title>. <source>J Am Coll Cardiol</source>. <year>2010</year>;<volume>56</volume>(<issue>15</issue>):<fpage>1207</fpage>–<lpage>1213</lpage>.</citation></ref>
<ref id="bibr28-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stiller</surname><given-names>B</given-names></name><name><surname>Lemmer</surname><given-names>J</given-names></name><name><surname>Merkle</surname><given-names>F</given-names></name><etal/></person-group> <article-title>Consumption of blood products during mechanical circulatory support in children: comparison between ECMO and a pulsatile ventricular assist device</article-title>. <source>Intensive Care Med</source>. <year>2004</year>;<volume>30</volume>(<issue>9</issue>):<fpage>1814</fpage>–<lpage>1820</lpage>.</citation></ref>
<ref id="bibr29-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Genovese</surname><given-names>EA</given-names></name><name><surname>Dew</surname><given-names>MA</given-names></name><name><surname>Teuteberg</surname><given-names>JJ</given-names></name><etal/></person-group> <article-title>Incidence and patterns of adverse event onset during the first 60 days after ventricular assist device implantation</article-title>. <source>Ann Thorac Surg</source>. <year>2009</year>;<volume>88</volume>(<issue>4</issue>):<fpage>1162</fpage>–<lpage>1170</lpage>.</citation></ref>
<ref id="bibr30-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Seibel</surname><given-names>K</given-names></name><name><surname>Berdat</surname><given-names>P</given-names></name><name><surname>Boillat</surname><given-names>C</given-names></name><name><surname>Wagner</surname><given-names>B</given-names></name><name><surname>Zachariou</surname><given-names>Z</given-names></name><name><surname>Kessler</surname><given-names>U</given-names></name></person-group>. <article-title>Hemostasis management in pediatric mechanical circulatory support</article-title>. <source>Ann Thorac Surg</source>. <year>2008</year>;<volume>85</volume>(<issue>4</issue>):<fpage>1453</fpage>–<lpage>1456</lpage>.</citation></ref>
<ref id="bibr31-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stiller</surname><given-names>B</given-names></name><name><surname>Lemmer</surname><given-names>J</given-names></name><name><surname>Schubert</surname><given-names>S</given-names></name><etal/></person-group> <article-title>Management of pediatric patients after implantation of the Berlin Heart EXCOR ventricular assist device</article-title>. <source>ASAIO J</source>. <year>2006</year>;<volume>52</volume>(<issue>5</issue>):<fpage>497</fpage>–<lpage>500</lpage>.</citation></ref>
<ref id="bibr32-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Drews</surname><given-names>T</given-names></name><name><surname>Stiller</surname><given-names>B</given-names></name><name><surname>Hubler</surname><given-names>M</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>Berger FHetzer</surname><given-names>R</given-names></name></person-group>. <article-title>Coagulation management in pediatric mechanical support</article-title>. <source>ASAIO</source>. <year>2007</year>;<volume>53</volume>(<issue>5</issue>):<fpage>640</fpage>–<lpage>645</lpage>.</citation></ref>
<ref id="bibr33-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghez</surname><given-names>O</given-names></name><name><surname>Liesner</surname><given-names>R</given-names></name><name><surname>Karimova</surname><given-names>A</given-names></name><name><surname>Ng</surname><given-names>C</given-names></name><name><surname>Goldman</surname><given-names>A</given-names></name><name><surname>Van</surname><given-names>DC</given-names></name></person-group>. <article-title>Subcutaneous low molecular weight heparin for management of anticoagulation in infants on excor ventricular assist device</article-title>. <source>ASAIO J</source>. <year>2006</year>;<volume>52</volume>(<issue>6</issue>):<fpage>705</fpage>–<lpage>707</lpage>.</citation></ref>
<ref id="bibr34-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tsukui</surname><given-names>H</given-names></name><name><surname>Abla</surname><given-names>A</given-names></name><name><surname>Teuteberg</surname><given-names>JJ</given-names></name><etal/></person-group> <article-title>Cerebrovascular accidents in patients with a ventricular assist device</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2007</year>;<volume>134</volume>(<issue>1</issue>):<fpage>114</fpage>–<lpage>123</lpage>.</citation></ref>
<ref id="bibr35-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bembea</surname><given-names>MM</given-names></name><name><surname>Savage</surname><given-names>W</given-names></name><name><surname>Strouse</surname><given-names>JJ</given-names></name><etal/></person-group> <article-title>Glial fibrillary acidic protein as a brain injury biomarker in children undergoing extracorporeal membrane oxygenation</article-title>. <source>Pediatr Crit Care Med</source>. <year>2011</year>;<volume>12</volume>(<issue>5</issue>):<fpage>572</fpage>–<lpage>579</lpage>.</citation></ref>
<ref id="bibr36-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulman</surname><given-names>AR</given-names></name><name><surname>Martens</surname><given-names>TP</given-names></name><name><surname>Christos</surname><given-names>PJ</given-names></name><etal/></person-group> <article-title>Comparisons of infection complications between continuous flow and pulsatile flow left ventricular assist devices</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2007</year>;<volume>133</volume>(<issue>3</issue>):<fpage>841</fpage>–<lpage>842</lpage>.</citation></ref>
<ref id="bibr37-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kouretas</surname><given-names>PC</given-names></name><name><surname>Burch</surname><given-names>PT</given-names></name><name><surname>Kaza</surname><given-names>AK</given-names></name><etal/></person-group> <article-title>Management of deep wound complications with vacuum-assisted therapy after Berlin Heart EXCOR ventricular assist device placement in the pediatric population</article-title>. <source>Artif Organs</source>. <year>2009</year>;<volume>33</volume>(<issue>11</issue>):<fpage>922</fpage>–<lpage>925</lpage>.</citation></ref>
<ref id="bibr38-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stepanenko</surname><given-names>A</given-names></name><name><surname>Pasic</surname><given-names>M</given-names></name><name><surname>Potapov</surname><given-names>EV</given-names></name><name><surname>Weng</surname><given-names>Y</given-names></name><name><surname>Krabatsch</surname><given-names>T</given-names></name><name><surname>Hetzer</surname><given-names>R</given-names></name></person-group>. <article-title>Accidental intraperitoneal tunneling of driveline of left ventricular assist device</article-title>. <source>Ann Thorac Surg</source>. <year>2010</year>;<volume>90</volume>(<issue>5</issue>):<fpage>1690</fpage>–<lpage>1691</lpage>.</citation></ref>
<ref id="bibr39-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bhama</surname><given-names>JK</given-names></name><name><surname>Rayappa</surname><given-names>S</given-names></name><name><surname>Zaldonis</surname><given-names>D</given-names></name><etal/></person-group> <article-title>Impact of abdominal complications on outcome after mechanical circulatory support</article-title>. <source>Ann Thorac Surg</source>. <year>2010</year>;<volume>89</volume>(<issue>2</issue>):<fpage>522</fpage>–<lpage>528</lpage>.</citation></ref>
<ref id="bibr40-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goda</surname><given-names>A</given-names></name><name><surname>Takayama</surname><given-names>H</given-names></name><name><surname>Pak</surname><given-names>SW</given-names></name><etal/></person-group> <article-title>Aortic valve procedures at the time of ventricular assist device placement</article-title>. <source>Ann Thorac Surg</source>. <year>2011</year>;<volume>91</volume>(<issue>3</issue>):<fpage>750</fpage>–<lpage>754</lpage>.</citation></ref>
<ref id="bibr41-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>AS</given-names></name><name><surname>Holman</surname><given-names>WL</given-names></name><name><surname>Nanda</surname><given-names>NC</given-names></name><etal/></person-group> <article-title>Native aortic valve insufficiency in patients with left ventricular assist devices</article-title>. <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>81</volume>(<issue>2</issue>):<fpage>e6</fpage>–<lpage>e8</lpage>.</citation></ref>
<ref id="bibr42-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tasset</surname><given-names>MR</given-names></name><name><surname>Kavarana</surname><given-names>MN</given-names></name><name><surname>Gray</surname><given-names>LA</given-names></name><name><surname>Dowling</surname><given-names>RD</given-names></name></person-group>. <article-title>Simple mechanical aortic valve closure in ventricular assist device recipients</article-title>. <source>Ann Thorac Surg</source>. <year>2006</year>;<volume>82</volume>(<issue>1</issue>):<fpage>316</fpage>–<lpage>318</lpage>.</citation></ref>
<ref id="bibr43-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Allan</surname><given-names>CK</given-names></name><name><surname>Thiagarajan</surname><given-names>RR</given-names></name><name><surname>del Nido</surname><given-names>PJ</given-names></name><name><surname>Roth</surname><given-names>SJ</given-names></name><name><surname>Almodovar</surname><given-names>MC</given-names></name><name><surname>Laussen</surname><given-names>PC</given-names></name></person-group>. <article-title>Indication for initiation of mechanical circulatory support impacts survival of infants with shunted single-ventricle circulation supported with extracorporeal membrane oxygenation</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2007</year>;<volume>133</volume>(<issue>3</issue>):<fpage>660</fpage>–<lpage>667</lpage>.</citation></ref>
<ref id="bibr44-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ravishankar</surname><given-names>C</given-names></name><name><surname>Gaynor</surname><given-names>JW</given-names></name></person-group>. <article-title>Mechanical support of the functionally single ventricle</article-title>. <source>Cardiol Young</source>. <year>2006</year>;<volume>16</volume>(<issue>suppl 1</issue>):<fpage>55</fpage>–<lpage>60</lpage>.</citation></ref>
<ref id="bibr45-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>KL</given-names></name><name><surname>Roth</surname><given-names>SJ</given-names></name><name><surname>Thiagarajan</surname><given-names>RR</given-names></name><name><surname>Almodovar</surname><given-names>MC</given-names></name><name><surname>del Nido</surname><given-names>PJ</given-names></name><name><surname>Laussen</surname><given-names>PC</given-names></name></person-group>. <article-title>Extracorporeal membrane oxygenation support of the Fontan and bidirectional Glenn circulations</article-title>. <source>Ann Thorac Surg</source>. <year>2004</year>;<volume>77</volume>(<issue>4</issue>):<fpage>1341</fpage>–<lpage>1348</lpage>.</citation></ref>
<ref id="bibr46-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Throckmorton</surname><given-names>AL</given-names></name><name><surname>Ballman</surname><given-names>KK</given-names></name><name><surname>Myers</surname><given-names>CD</given-names></name><name><surname>Litwak</surname><given-names>KN</given-names></name><name><surname>Frankel</surname><given-names>SH</given-names></name><name><surname>Rodefeld</surname><given-names>MD</given-names></name></person-group>. <article-title>Mechanical cavopulmonary assist for the univentricular Fontan circulation using a novel folding propeller blood pump</article-title>. <source>ASAIO J</source>. <year>2007</year>;<volume>53</volume>(<issue>6</issue>):<fpage>734</fpage>–<lpage>741</lpage>.</citation></ref>
<ref id="bibr47-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Riemer</surname><given-names>RK</given-names></name><name><surname>Amir</surname><given-names>G</given-names></name><name><surname>Reichenbach</surname><given-names>SH</given-names></name><name><surname>Reinhartz</surname><given-names>O</given-names></name></person-group>. <article-title>Mechanical support of total cavopulmonary connection with an axial flow pump</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2005</year>;<volume>130</volume>(<issue>2</issue>):<fpage>351</fpage>–<lpage>354</lpage>.</citation></ref>
<ref id="bibr48-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>MW</given-names></name><name><surname>Sharma</surname><given-names>K</given-names></name><name><surname>Tchervenkov</surname><given-names>CI</given-names></name><etal/></person-group> <article-title>Berlin Heart ventricular assist device in a child with hypoplastic left heart syndrome</article-title>. <source>Ann Thorac Surg</source>. <year>2007</year>;<volume>83</volume>(<issue>3</issue>):<fpage>1179</fpage>–<lpage>1181</lpage>.</citation></ref>
<ref id="bibr49-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Irving</surname><given-names>CA</given-names></name><name><surname>Cassidy</surname><given-names>JV</given-names></name><name><surname>Kirk</surname><given-names>RC</given-names></name><name><surname>Griselli</surname><given-names>M</given-names></name><name><surname>Hasan</surname><given-names>A</given-names></name><name><surname>Crossland</surname><given-names>DS</given-names></name></person-group>. <article-title>Successful bridge to transplant with the Berlin Heart after cavopulmonary shunt</article-title>. <source>J Heart Lung Transplant</source>. <year>2009</year>;<volume>28</volume>(<issue>4</issue>):<fpage>399</fpage>–<lpage>401</lpage>.</citation></ref>
<ref id="bibr50-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pearce</surname><given-names>FB</given-names></name><name><surname>Kirklin</surname><given-names>JK</given-names></name><name><surname>Holman</surname><given-names>WL</given-names></name><name><surname>Barrett</surname><given-names>CS</given-names></name><name><surname>Romp</surname><given-names>RL</given-names></name><name><surname>Lau</surname><given-names>YR</given-names></name></person-group>. <article-title>Successful cardiac transplant after Berlin Heart bridge in a single ventricle heart: use of aortopulmonary shunt as a supplementary source of pulmonary blood flow</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2009</year>;<volume>137</volume>(<issue>1</issue>):<fpage>e40</fpage>–<lpage>e42</lpage>.</citation></ref>
<ref id="bibr51-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>M</given-names></name><name><surname>Baird</surname><given-names>C</given-names></name><name><surname>Fynn-Thompson</surname><given-names>F</given-names></name><etal/></person-group> <article-title>Successful implantation of a Berlin heart biventricular assist device in a failing single ventricle</article-title>. <source>J Thorac Cardiovasc Surg</source>. <year>2006</year>;<volume>131</volume>(<issue>6</issue>):<fpage>1407</fpage>–<lpage>1408</lpage>.</citation></ref>
<ref id="bibr52-2150135111420888"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Newcomb</surname><given-names>AE</given-names></name><name><surname>Negri</surname><given-names>JC</given-names></name><name><surname>Brizard</surname><given-names>CP</given-names></name><name><surname>d’Udekem</surname><given-names>Y</given-names></name></person-group>. <article-title>Successful left ventricular assist device bridge to transplantation after failure of a fontan revision</article-title>. <source>J Heart Lung Transplant</source>. <year>2006</year>;<volume>25</volume>(<issue>3</issue>):<fpage>365</fpage>–<lpage>367</lpage>.</citation></ref>
</ref-list>
</back>
</article>